TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF - News)(TSX:BVF - News) today announced that Ralivia™, the Company’s once-daily tramadol formulation, has been officially launched in Canada, and is now commercially available. Ralivia™ is indicated for the management of pain of moderate severity in patients who require continuous treatment for several days or more.
